Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

RBDCOV RBD Dimer recombinant protein vaccine against SARSCoV2

Coordinator
Hipra Scientific SL, Spain
Runs
1 December 2021 to 31 August 2025
Status
Running
EU funding
€9.8m
Total cost
€9.8m
Partners
20 organisations in 6 countries
Type
Research and Innovation Action
Grant agreement
101046118

What the project is doing

In the project's own words, from its summary on CORDIS.

The main objective of RBDCOV project is to test the efficacy, tolerability, and safety of a new vaccine against different variants of COVID-19 based on the outstanding data generated using a recombinant protein developed by the consortium partners. Two different clinical trials will be run during the project duration to test the variants recombinant RBD protein vaccine, codifying for Beta and Alpha SARS-Cov-2 variants in paediatric population and in immunocompromised adults.

The aim of the project is to focus not only on the current SARS-CoV-2 variants but also in the emerging ones as Beta and Alpha variants. Thus, a continuous monitoring of the new emerging variants will be performed throughout the project to ensure that the platform is prepared to cope with the disease. The platform used for the generation of the vaccines is adaptable to variants and will be ready to include in the design any other potential variant that could appear in short, medium and large term.

Preclinical data are already available. The core of RBDCOV consortium has been in close contact to the corresponding agencies and considering Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2, preclinical data supporting the first vaccine candidate can be extrapolated for the vaccines against the new emerging variants. This create a unique opportunity for RBDCOV consortium to generate the first RBD recombinant vaccine to be approved in Europe.

This vaccine will be manufactured by an European technological company that will change actual paradigms and allow the really change to One health concept, based on the close relationship between the animal world and the onset of certain infections in humans.

Topics

Who is involved

OrganisationCityCountryRole
Hipra Scientific SLAmerSpainCoordinator
European Aids Treatment Group eVDusseldorfGermanyParticipant
Asphalion SLBarcelonaSpainParticipant
Drug Development and Regulation SLBarcelonaSpainThird party
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainParticipant
Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaBarcelonaSpainParticipant
Fundacio Institut D'investigacio Biomedica De Girona Doctor Josep TruetaGironaSpainParticipant
Fundacio Privada Institut De Recerca Sobre Immunopatologies-Caixa, IrsicaixaBarcelonaSpainParticipant
Fundacion Fls De Lucha Contra Elsida Las Enfermedades Infecciosasy La Promocion De La Salud Y LacienciaBadalonaSpainParticipant
Hipra Human Health SLAmerSpainThird party
Hipra Sociedad AnonimaAmerSpainThird party
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Institut Catala De La SalutBarcelonaSpainThird party
Laboratorios Hipra SAAmer GironaSpainThird party
Vinces Consulting, SLMadridSpainParticipant
Zabala Innovation Consulting SAMutilva Alta NavarraSpainParticipant
Fondazione Penta EtsPadovaItalyParticipant
Metpharm Arastirma Gelistirme Saglik Danismanlik Limited SirketIstanbulTürkiyeParticipant
Veristat International LimitedLondonUnited KingdomParticipant
Veristat LlcWilmingtonUnited StatesThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI